SRSudhaker Dhanwada Rao

Sudhaker Dhanwada Rao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sudhaker Dhanwada Rao has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Aberrant Histone Methylation Profile in Patients with Sporadic Primary Hyperparathyroidism

    by Poonam Kumari, Sanjay Kumar Bhadada, Ashutosh Kumar Arya, Jyotdeep Kaur, Naresh Sachdeva, Uma Nahar Saikia, Divya Dahiya, Anoop Kumar, Chirag Kharbanda, Sudhaker D Rao

    Introduction: Primary hyperparathyroidism (PHPT) is a systemic endocrine disorder characterized by elevated PTH levels and hypercalcemia. Gene-specific epigenetic modifications like histone methylation play a pivotal role in PHPT by altering expression of parathyroid-specific genes. However, global histone modifications in parathyroid tumors and their implications for tumor behavior remain underexplored. Experimental Design: We performed comparative histone modification profiling in blood and tissue samples from sporadic parathyroid adenomas (PA; n = 30), atypical parathyroid tumors (APT; n = 05), and parathyroid carcinomas (PC; n = 05) along with controls using histone H3 multiplex immunoassay. Significantly dysregulated modifications were validated by Western blotting (WB), and expression data was correlated with clinicopathological features. We performed pathway enrichment analysis to elucidate molecular pathways potentially linked to histone H3 modifications in parathyroid tumorigenesis. Results: We observed dynamic alterations in histone H3 modifications of lysine (K) residues across parathyroid tumor phenotypes in blood and tissue samples. A reduction in H3K4 and H3K36 trimethylation (130%) compared to controls was observed. WB confirmed lower H3K4me3 (0.5 ± 0.4 vs 4.4 ± 0.7, P = .02; 0.4 ± 0.2 vs 4.4 ± 0.7, P = .004) and H3K36me3 (0.4 ± 0.2 vs 1.0 ± 0.3, P = .03; 0.2 ± 0.1 vs 1.0 ± 0.3, P = .02) in APT and PC than controls and higher H3K27me3 expression in PA (2.9 ± 1.2 vs 1.1 ± 0.21, P = .04), APT (4.2 ± 2.9 vs 1.1 ± 0.21, P = .007), and PC (6.9 ± 3.1 vs 1.1 ± 0.21, P = .0002) relative to controls. Pathway enrichment analysis identified molecular pathways, including calcium signaling, Wnt, and Hippo signaling, associated with histone H3 modifications. Conclusion: Increased expression of repressive H3K27me3 in blood and tissue samples, while decreased H3K4me3 and H3K36me3, suggest a shift toward transcriptional repression. Identifying their functional mechanisms may facilitate the discovery of novel insights for therapeutic targeting in parathyroid tumors.

  • Effects of Hypopituitarism Due to Sheehan's Syndrome on Bone Mineral Density: A Multicentric Study in Asian Indians

    by Liza Das, Jayaprakash Sahoo, Bashir Ahmad Laway, Sailesh Bansiwal, Paramjeet Singh, Márta Korbonits, Sudhaker Dhanwada Rao, Sanjay Kumar Bhadada, Pinaki Dutta

    Context: Sheehan's syndrome (SS) is a rare cause of hypopituitarism. Data on skeletal health in patients with this condition is limited and predictors of low bone mineral density (BMD) are not well elucidated. We aimed to explore hormonal profile and BMD in a large multicentric cohort of treated SS patients. Design and Patients: The study recruited patients with SS on stable hormone replacement (n = 110) and healthy female controls ( n = 102). The hormonal profile (cortisol, DHEAS, T4, TSH, prolactin, IGF1) was analyzed. Bone turnover markers (P1NP, β‐CTX) were estimated by electrochemiluminescence assay. BMD was evaluated using DXA. Prevalence and predictors of low BMD were assessed. Results: The cohort comprised 110 patients with SS with a mean age of 45.3 ± 10.5 years and a delay of 7.9 ± 6.3 years from disease onset to diagnosis. Patients were on glucocorticoid (94.6%) and levothyroxine (90.5%) replacement, with prior exposure to estrogen‐progestin (66.7%). Bone turnover markers were not significantly different between the two groups. Low BMD (osteopenia/osteoporosis) was prevalent in a significantly greater proportion of the cases as compared to controls at the lumbar spine (94% vs 47%) and femoral neck (80% vs 36%). The most important predictor of low BMD at the lumbar spine was the length of delay prior to diagnosis (OR 1.48 (95% CI 1.002‐2.206), p = 0.04). Conclusion: SS is characterized by a high prevalence of multiple pituitary hormone deficiencies, including hypoprolactinaemia. Low BMD is highly prevalent in SS compared to age, and BMI‐matched controls. Despite adequate relevant hormone replacement therapy, a longer delay in diagnosing is the major determinant of low BMD in patients with SS.

  • Open Access

    Grading Pseudo Fractures

    by Sudhaker D. Rao

  • Preface

    by Sanjay Kumar Bhadada, Liza Das, Rimesh Pal, D. Sudhaker Rao

  • Enhancer of zeste homolog 2 (EZH2) in endocrine tumors: current knowledge and future directions

    by Poonam Kumari, Sheenam Garg, Ashutosh Kumar Arya, Jyotdeep Kaur, Naresh Kumar Sachdeva, Uma Nahar Saikia, Divya Dahiya, Sanjay Kumar Bhadada, Sudhaker D. Rao

    Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that orchestrates gene expression via epigenetic and non-epigenetic mechanisms. EZH2 performs epigenetic functions by methylating histones and/or non-histone proteins and suppressing or activating target genes. Moreover, non-epigenetic functions involve dysregulation of target genes independent of histone methylation, thereby impacting multiple signaling pathways. EZH2 has emerged as a pivotal player in the initiation of various cancers. EZH2 overexpression facilitated by H3K27me3 is the principal driver. However, the consequent dysregulation of target genes resulting from EZH2 overexpression has emerged as a secondary instigator of tumorigenesis, leading to metastasis and poor prognosis. Further complexity arises from somatic mutations in EZH2 and downstream target genes such as BRAF and RASSF1A. However, understanding its effects on endocrine tumors/cancers remains an underexplored with the potential to significantly enhance clinical outcomes and contribute to human health. Therefore, the present review focuses on the multifaceted functions of EZH2 and its pathophysiological mechanisms in tumor proliferation, with a specific emphasis on endocrine tumors. Investigating EZH2 mechanisms and targeting with inhibitors and drugs is an active area of research that could offer a promising avenue for treatment and a better understanding of molecular therapeutic interventions.


  • Facet joint distance measurement using digital tomosynthesis while standing

    by Daniel Oravec, Razeen Zaman, Sudhaker Rao, Victor Chang, George Divine, Yener N. Yeni


  • Open Access

    Impact of anti-fracture medications on bone material and strength properties: a systematic review and meta-analysis

    by Shivani Sharma, Vijay Shankar, Singh Rajender, Ambrish Mithal, Sudhaker D. Rao, Naibedya Chattopadhyay

    Background and aims: Reduced bone mineral density (BMD) and microarchitectural deterioration contribute to increased fracture risk. Although the effects of anti-fracture medications (AFMs) on BMD are well-documented, their impact on bone material properties (BMPs) remains poorly characterized. Accordingly, we conducted a systematic review and meta-analysis to evaluate the effects of AFMs on BMPs. Based on data availability, we further categorized AFMs into anti-resorptives, bisphosphonates alone, and strontium ranelate subgroups to perform additional analyses of BMPs in osteoporotic patients.Methods: We did a comprehensive search of three databases, namely, PubMed, Web of Science, and Google Scholar, using various permutation combinations, and used Comprehensive Meta-Analysis software to analyze the extracted data.Results: The 15 eligible studies (randomized and non-randomized) compared the following: (1) 301 AFM-treated patients with 225 on placebo; (2) 191 patients treated with anti-resorptives with 131 on placebo; (3) 86 bisphosphonate-treated patients with 66 on placebo; and (4) 84 strontium ranelate-treated patients with 70 on placebo. Pooled analysis showed that AFMs significantly decreased cortical bone crystallinity [standardized difference in means (SDM) −1.394] and collagen maturity [SDM −0.855], and collagen maturity in cancellous bone [SDM −0.631]. Additionally, anti-resorptives (bisphosphonates and denosumab) significantly increased crystallinity [SDM 0.387], mineral–matrix ratio [SDM 0.771], microhardness [SDM 0.858], and contact hardness [SDM 0.952] of cortical bone. Anti-resorptives increased mineral–matrix ratio [SDM 0.543] and microhardness [SDM 0.864] and decreased collagen maturity [SDM −0.539] in cancellous bone. Restricted analysis of only bisphosphonate-treated studies showed a significant decrease in collagen maturity [SDM −0.650] in cancellous bone and an increase in true hardness [SDM 1.277] in cortical bone. In strontium ranelate-treated patients, there was no difference in BMPs compared to placebo.Conclusion: Collectively, our study suggests that AFMs improve bone quality, which explains their anti-fracture ability that is not fully accounted for by increased BMD in osteoporosis patients.


  • Open Access

    Differences in tissue-level properties as assessed by nano-scratching in patients with and without atypical femur fractures on long-term bisphosphonate therapy: a proof-of-concept pilot study

    by Gabriel Johnson, Lanny V Griffin, Shijing Qiu, Sudhaker D Rao

    Atypical femur fractures (AFFs) are a well-established complication of long-term bisphosphonate (BP) therapy, but their pathogenesis is not fully understood. Although many patients on long-term BP therapy have severe suppression of bone turnover (SSBT), not all such patients experience AFF, even though SSBT is a major contributor to AFF. Accordingly, we evaluated tissue level properties using nano-scratch testing of trans-iliac bone biopsy specimens in 12 women (6 with and 6 without AFF matched for age and race). Nano-scratch data were analyzed using a mixed-model ANOVA with volume-normalized scratch energy as a function of AFF (Yes or No), region (periosteal or endosteal), and a first-order interaction between region and AFF. Tukey post hoc analyses of the differences of least squared means of scratch energy were performed and reported as significant if p<.05. The volume-normalized scratch energy was 10.6% higher in AFF than in non-AFF patients (p=.003) and 17.9 % higher in the periosteal than in the endosteal region (p=.004). The differences in normalized scratch energy are suggestive of a higher hardness of the bone tissue after long-term BP therapy. The results of this study are consistent with other studies in the literature and demonstrate the efficacy of using Nano-Scratch technique to evaluate bone tissue that exhibits SSBT and AFF. Further studies using nano-scratch may help quantify and elucidate underlying mechanisms for the pathogenesis of AFF. Thigh bone fractures, known as atypical femur fractures (AFFs), are a well-established but rare complication of long-term therapy with certain anti-fracture medications known as bisphosphonates or denosumab, but their cause is not fully understood. In this pilot study, we evaluated tissue level mechanical properties using nano-scratch testing of trans-iliac bone biopsy specimens in 12 women (6 with and 6 without AFF matched for age and race). Nano-scratch technique measures the energy required to indent a region of bone tissue biopsies from patients with and without thigh-bone fractures. Our results are suggestive of a higher hardness of the bone tissue after long-term anti-fracture therapy. Also, our results from this study are consistent with other studies and demonstrate the efficacy of using Nano-Scratch technique to evaluate bone tissue properties. Further studies using this technique may help quantify and elucidate underlying mechanisms for AFF.